medigraphic.com
ISSN 2070-8718 (Print)

2017, Number 2

<< Back Next >>

Rev Cub Gen 2017; 11 (2)

Use of VIMANG ® in the treatment of patients with early onset neuromuscular diseases

Riverón FG, Lantigua CA, Pérez BG, Guevara GM, Tassé VD, Martínez BO, Lemus MG, Marín PLC

Language: Spanish
References: 26
Page: 23-30
PDF size: 330.57 Kb.


ABSTRACT

Oxidative stress has been proposed as one of the pathogenic mechanisms involved in the development and progression of multiple clinical entities, including neuromuscular diseases. The application of therapeutic strategies based on the use of protective agents with antioxidant capacity could be an alternative in the treatment of these patients. The aim of this study was to evaluate the clinical, biochemical and oxidative stress outcome after the use of VIMANG® in the treatment of patients with clinical diagnosis of neuromuscular diseases. The treatment was applied for six months to four patients with neuromuscular diseases treated at the Genetic Clinic of Juan Manuel Marquez Hospital. Before starting treatment with VIMANG®, all patients were clinically evaluated and biochemical parameters were determined. At six months of treatment, the patients were reevaluated. Before the use of VIMANG®, patients had altered muscular strength, two patients were malnourished and some alterations were observed in some biochemical parameters including markers of oxidative stress. After six months of treatment, qualitative clinical improvements and a tendency to decrease oxidation product concentrations at the systemic level were observed, although an improvement in the efficiency of the endogenous enzymatic antioxidant system was not achieved. Conclusions: The results suggest that VIMANG® can be used in the treatment of patients with genetic diseases that present progressive muscular deterioration. Oxidative stress markers may be useful in the clinical follow-up of patients with these diseases, but further studies and a larger number of patients will be required to extend the use of this antioxidant in the care protocol of these patients.


REFERENCES

  1. Tidball JG, Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007;102: 1677-86.

  2. Moulin M, Ferreiro A. Muscle redox disturbances and oxidative stress as pathomechanisms and therapeutic targets in early-onset myopathies. Semin Cell Dev Biol 2017;64:213-23.

  3. Kleinsteuber K, Avaria MA. Enfermedades Neuromusculares en Pediatría. Rev Ped Elec 2005;2(1):52-61.

  4. Woodman KG, Coles CA, Lamandé SR, White JD. Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture. Nutrients 2016; 8(11).pii: E713.

  5. Rapucci LH, Dias R, de Almeida T, Sayuri D, Barbosa A, Minate E. Effects of antioxidant and iron chelator combined therapy in the skeletal muscle of mdx mice. Perspectivas Médicas 2017;28(1):29-37.

  6. Dowling JJ, Arbogast S, Hur J, Nelson DD, McEvoy A, Waugh T, et al. Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy. Brain 2012; 135;1115–27.

  7. Nabukera SK, Romitti PA, Campbell KA, Meaney FJ, Caspers KM, Mathews KD, et al. Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy. J Child Neurol 2012;27:734–40.

  8. Chahbouni M, Escames G, Venegas C, Sevilla B, Garcia JA, Lopez LC, Munoz-Hoyos A, et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010;48:282–9.

  9. Choi MH, Ow JR, Yang ND, Taneja R. Oxidative stress-mediated skeletal muscle degeneration: molecules, mechanisms, and therapies. Oxid Med Cell Longev 2016;2016:6842568.

  10. Núñez Sellés AJ. Terapia antioxidante, estrés oxidativo y productos antioxidantes: retos y oportunidades. Rev Cub Salud Pub 2011; 37(Suppl 5): 644-60.

  11. Kozakowska M, Pietraszek-Gremplewicz K, Jozkowicz A, Dulak J. The role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymes. J Muscle Res Cell Motil 2015;36(6):377-93.

  12. Garrido G, González D, Lemus Y, García D, Lodeiro L, Quintero G, D, et al. In vivo and in vitro anti-inflammatory activity of Mangiferaindica L. extract (VIMANG). Pharmacol Res 2004;50(2):143-9.

  13. Martínez Sánchez G, Giuliani A, León Fernández OS, Pérez Davison G, Núñez Sellés AJ. Effect of Mangifera indica L. extract (Vimang) on protein and hepatic microsome peroxidation. Phytother Res 2001;15:581-5.

  14. Valverde S, Duarte EM, Ducangé D, Garrido G, García-Rivera D, Jáuregui U, et al. Utilidad de las formulaciones Vimang® en pacientes con osteoartrosis de rodilla. Rev Soc Esp Dolor 2009;16(1):32-41.

  15. Pardo-Andreu GL, Philip S Jr, Riaño A, Sánchez C, Viada C, Núñez-Sellés AJ, et al. Natural extract from stem bark of Mangifera indica L. (Vimang) protects against serum oxidative stress related with age in elderly humans. Arch Med Res 2006;37:158-64.

  16. Gil L, León OS, Perez J, González I, Milián LC, Guevara M. Characterization of oxidative stress in different clinical conditions, using redox índices of diagnostic value. Biotecnol Apl 2012;29(3):175-83.

  17. Pérez C, Riverón G, Fernández I, del Castillo NP, Martínez O, Gutiérrez R et al. Marcadores de estrés oxidativo y genotoxicidad en trabajadores cubanos con exposición ocupacional prolongada al plomo. Rev Cub Salud y Trabajo 2015;16(3):20-5.

  18. Carter GT. Rehabilitation Management of Neuromuscular Disease. [Citado 15 Ago 2017].Disponible en: http://emedicine.medscape.com/article/321397.

  19. Miller ML. Muscle enzymes in the evaluation of neuromuscular diseases. [Citado 15 Ago 2017]. Disponible en: http://www.uptodate.com/contents/muscle-enzymes-in-the-evaluation-of-neuromuscular-diseases.

  20. Nakae Y, Dorchies OM, Stoward PJ, Zimmermann BF, Ritter C, Ruegg UT. Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechingallate, an antioxidant polyphenol from green tea. Histochem Cell Biol 2012;137:811–27.

  21. Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006;26:1156-62.

  22. Garrido-Suárez BB, Garrido G, Delgado R, Bosch F, del C Rabí M. A Mangiferaindica L. extract could be used to treat neuropathic pain and implication of mangiferin. Molecules 2010;15(12):9035-45.

  23. Hori YS, Kuno A, Hosoda R, Tanno M, Miura T, Shimamoto K, Horio Y. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for duchenne muscular dystrophy. J Pharmacol Exp Ther 2011;338:784–94.

  24. Gordon BS, Delgado Diaz DC, Kostek MC. Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin Nutr 2013;32:104–111.

  25. Sánchez-Rodríguez MA, Santiago-Osorio E, Vargas LA, Mendoza-Núñez VM. Propuesta de un constructo para evaluar integralmente el estrés oxidativo. Bioquimia 2004;29(3):81-90.

  26. Méplan C. Selenium and Chronic Diseases: A Nutritional Genomics Perspective Nutrients 2015;7(5):3621–51.




2020     |     www.medigraphic.com